Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | AHR | P35869 | 2/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040124 | 1.00 | PDE3B (0.66) | PDE3BPDE3ASRCGAAMAOB | |
| SCHEMBL3285782 | 0.91 | NPC1 (0.59) | PDE3BPDE3ASRCGAAMAOB | |
| SCHEMBL155069 | 0.88 | PDE3B (0.62) | PDE3BPDE3ASRCGAAMAOB | |
| Trifluoroacetic Acid SCHEMBL29921460 | 0.87 | PDE3B (0.52) | PDE3BPDE3ASRCGAAMAOB | |
| SCHEMBL153506 | 0.86 | EIF2AK2 (0.74) | PDE3BPDE3ASRCGAAMAOB | |
| SCHEMBL1764375 | 0.84 | PKM (0.65) | PDE3BPDE3AMAOBMAOAALDH1A1 | |
| SCHEMBL30094448 | 0.84 | PDE3B (0.68) | PDE3BPDE3AGAAMAOBMAOA | |
| SCHEMBL29853437 | 0.83 | PDE3B (0.59) | PDE3BPDE3ASRCGAAMAOB | |
| SCHEMBL26767523 | 0.83 | PDE3B (0.59) | PDE3BPDE3ASRCGAAMAOB | |
| SCHEMBL1897771 | 0.83 | TDP2 (0.75) | PDE3BPDE3ASRCGAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194833-B | Catalyst system for initiating lactide ring-opening polymerization and preparation method of polylactic acid | 中国科学技术大学 | 2020-10-27 | — | — | CN | claimed |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | claimed |
| JP-2002540096-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| US-20260108527-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4598912-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250128203-A1 | MODIFIED REDOX-ACTIVE SORBENTS FOR ELECTROCHEMICAL CARBON DIOXIDE SEPARATION | THE JOHNS HOPKINS UNIVERSITY | 2025-04-24 | — | — | US | disclosed |
| CN-119371391-A | Aroyl compound and preparation method and application thereof | 河北医科大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-114206857-B | Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions comprising the same | 韩国生命工学研究院 | 2024-09-06 | — | — | CN | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-4556672-A | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0156603-A2 | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155828-A2 | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153818-A2 | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| WO-1983002610-A1 | DERIVATIVES OF 3,3-DIALKYL-INDOLIN AND OF 3,3-ALKYLENE-INDOLIN, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SANDOZ AG (CH) | 1983-08-04 | — | — | WO | disclosed |
| US-4224333-A | Antihypertensive 2H-indol-2-ones | ROUSSEL UCLAF (FR) | 1980-09-23 | — | — | US | disclosed |
| US-3960926-A | Process for preparing azasulfonium halide salts | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3954797-A | Process for preparing azasulfonium halide salts | CHROMALLOY AMERICAN CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108527-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PDE3B 3112/4885PDE3A 3804/4885SRC 307/4885 |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | PDE3B 1337/4885PDE3A 1630/4885SRC 11/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PDE3B 1399/4885PDE3A 1712/4885SRC 478/4885 |
| US-20250128203-A1 | MODIFIED REDOX-ACTIVE SORBENTS FOR ELECTROCHEMICAL CARBON DIOXIDE SEPARATION | SCO2, ENO1, PPOX | PDE3B 1663/4885PDE3A 1215/4885SRC 2702/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PDE3B 1364/4885PDE3A 1670/4885SRC 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.